Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation.
Charlson comorbidity index
SBRT
early stage NSCLC
overdiagnosis
overtreatment
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
17
10
2018
revised:
11
12
2018
accepted:
12
12
2018
pubmed:
9
1
2019
medline:
8
2
2020
entrez:
9
1
2019
Statut:
ppublish
Résumé
Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. One hundred and sixty three patients with NSCLC I-IIb (T3 N0) treated between 2002 and 2016 were eligible: 123 (75%) had pathological confirmation of disease, whereas 40 (25%) did not. In accordance with international guidelines, both groups received radiotherapy. Comorbidity was assessed with the Charlson Comorbidity Index (CCI). The median follow-up was 28.6 months (range: 0.3-162): 66 (40%) patients are still alive, while 97 (59%) patients died: 48 (29%) cancer-related deaths and 49 (30%) from causes other than cancer. Median overall survival (OS) in patients without pathological confirmation was 58.6 months (range: 0.5-162), which did not differ from those with microscopic proof of disease (39.4 months, range: 0.3-147.5; logrank P = 0.481). Median cancer-specific survival (CSS) also did not differ at 113.4 months (range: 0.5-162) in the non-confirmation group (logrank P = 0.763) versus 51.5 months (range: 3.7-129.5) in patients with pathology. In Cox regression, a CCI of ≥ 3 was associated with poor OS (hazard ratio 2.0; range 1.2-3.4; P = 0.010) and CSS (hazard ratio 2.0; 1.0-4.0; P = 0.043). OS and CSS in early lung cancer patients depend on comorbidity rather than on pathological confirmation of disease.
Sections du résumé
BACKGROUND
Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared.
METHODS
One hundred and sixty three patients with NSCLC I-IIb (T3 N0) treated between 2002 and 2016 were eligible: 123 (75%) had pathological confirmation of disease, whereas 40 (25%) did not. In accordance with international guidelines, both groups received radiotherapy. Comorbidity was assessed with the Charlson Comorbidity Index (CCI).
RESULTS
The median follow-up was 28.6 months (range: 0.3-162): 66 (40%) patients are still alive, while 97 (59%) patients died: 48 (29%) cancer-related deaths and 49 (30%) from causes other than cancer. Median overall survival (OS) in patients without pathological confirmation was 58.6 months (range: 0.5-162), which did not differ from those with microscopic proof of disease (39.4 months, range: 0.3-147.5; logrank P = 0.481). Median cancer-specific survival (CSS) also did not differ at 113.4 months (range: 0.5-162) in the non-confirmation group (logrank P = 0.763) versus 51.5 months (range: 3.7-129.5) in patients with pathology. In Cox regression, a CCI of ≥ 3 was associated with poor OS (hazard ratio 2.0; range 1.2-3.4; P = 0.010) and CSS (hazard ratio 2.0; 1.0-4.0; P = 0.043).
CONCLUSION
OS and CSS in early lung cancer patients depend on comorbidity rather than on pathological confirmation of disease.
Identifiants
pubmed: 30618120
doi: 10.1111/1759-7714.12966
pmc: PMC6360228
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
321-329Informations de copyright
© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Ann Oncol. 2017 May 1;28(5):1117-1123
pubmed: 28327906
N Engl J Med. 1999 Oct 14;341(16):1198-205
pubmed: 10519898
J Thorac Oncol. 2017 Dec;12(12):1755-1765
pubmed: 28962947
J Thorac Oncol. 2016 Jul;11(7):1112-20
pubmed: 27109322
Mayo Clin Proc. 1999 Apr;74(4):319-29
pubmed: 10221459
Lung Cancer. 2015 Jul;89(1):27-30
pubmed: 25864782
Chest. 2014 Oct;146(4):1021-1028
pubmed: 24853550
J Thorac Oncol. 2012 Jan;7(1):10-9
pubmed: 22173661
Int J Cancer. 2003 Mar 1;103(6):792-802
pubmed: 12516101
Eur J Radiol. 2003 Jan;45(1):60-8
pubmed: 12499065
Chest. 2005 Oct;128(4):2490-6
pubmed: 16236914
Ann Thorac Surg. 2009 Sep;88(3):917-22; discussion 922-3
pubmed: 19699920
J Am Coll Surg. 2007 Dec;205(6):729-34
pubmed: 18035254
Int J Cancer. 2007 Feb 15;120(4):868-74
pubmed: 17131307
Strahlenther Onkol. 2015 Mar;191(3):256-63
pubmed: 25245469
Chest. 2013 May;143(5 Suppl):e93S-e120S
pubmed: 23649456
Strahlenther Onkol. 2018 Sep;194(9):815-823
pubmed: 29802434
J Clin Oncol. 2010 Mar 10;28(8):1380-6
pubmed: 20142596
Acad Radiol. 2015 Aug;22(8):976-82
pubmed: 25772581
Radiother Oncol. 2005 May;75(2):165-70
pubmed: 16086907
J Thorac Oncol. 2015 Feb;10(2):272-9
pubmed: 25371078
J Thorac Oncol. 2017 Mar;12(3):510-519
pubmed: 28017592
Radiat Oncol. 2013 Mar 05;8:49
pubmed: 23497555
Lung Cancer. 2014 Sep;85(3):390-4
pubmed: 25001510
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Radiother Oncol. 2015 Feb;114(2):138-47
pubmed: 25497873
Strahlenther Onkol. 2018 Feb;194(2):91-97
pubmed: 28812120
J Clin Oncol. 2010 Dec 10;28(35):5153-9
pubmed: 21041709
Radiother Oncol. 2011 Nov;101(2):240-4
pubmed: 21775007
Strahlenther Onkol. 2014 Jan;190(1):26-33
pubmed: 24052011
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):348-53
pubmed: 22104360
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1394-9
pubmed: 20646856
Strahlenther Onkol. 2017 Oct;193(10):780-790
pubmed: 28567503
Lancet. 2002 Apr 20;359(9315):1388-93
pubmed: 11978336
J Clin Epidemiol. 2004 Dec;57(12):1288-94
pubmed: 15617955
Radiother Oncol. 2011 Nov;101(2):250-4
pubmed: 22056535
Chest. 2007 Sep;132(3 Suppl):234S-242S
pubmed: 17873171
Chest. 2009 Dec;136(6):1612-1617
pubmed: 19429718